Stockscreener 앱 받기
9.52
4.27%
0.39
시간 외 거래:
9.53
0.010
+0.11%
전일 마감가:
$9.13
열려 있는:
$9.07
하루 거래량:
50,638
Relative Volume:
0.66
시가총액:
$86.12M
수익:
$123.24M
순이익/손실:
$136.00K
주가수익비율:
-476.00
EPS:
-0.02
순현금흐름:
$-148.99M
1주 성능:
+7.21%
1개월 성능:
-28.96%
6개월 성능:
-50.83%
1년 성능:
-37.77%
1일 변동 폭
$8.96
$9.60
1주일 범위
$8.56
$9.60
52주 변동 폭
$6.53
$29.98
Seres Therapeutics Inc Stock (MCRB) Company Profile
명칭
Seres Therapeutics Inc
전화
617 945 9626
주소
200 SIDNEY STREET, CAMBRIDGE, MA
Compare MCRB vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MCRB
Seres Therapeutics Inc
|
9.52 | 82.59M | 123.24M | 136.00K | -148.99M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.14 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-08 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2024-10-24 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-04-21 | 개시 | JP Morgan | Neutral |
| 2021-07-23 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-03-05 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2020-09-18 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2020-08-18 | 개시 | Piper Sandler | Overweight |
| 2020-08-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-11 | 업그레이드 | Jefferies | Hold → Buy |
| 2019-04-30 | 개시 | Jefferies | Hold |
| 2018-10-22 | 개시 | Chardan Capital Markets | Buy |
| 2017-10-13 | 개시 | Oppenheimer | Outperform |
| 2017-08-04 | 재확인 | H.C. Wainwright | Buy |
| 2017-02-01 | 재확인 | FBR & Co. | Outperform |
| 2016-08-12 | 재확인 | FBR Capital | Outperform |
| 2016-08-01 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2016-08-01 | 재확인 | H.C. Wainwright | Buy |
| 2016-07-29 | 재개 | H.C. Wainwright | Buy |
| 2016-03-30 | 개시 | FBR Capital | Outperform |
| 2016-03-03 | 개시 | Guggenheim | Buy |
| 2016-01-25 | 개시 | H.C. Wainwright | Buy |
| 2015-10-22 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2015-07-22 | 개시 | Canaccord Genuity | Buy |
| 2015-07-21 | 개시 | Goldman | Neutral |
| 2015-07-21 | 개시 | Leerink Partners | Outperform |
모두보기
Seres Therapeutics Inc 주식(MCRB)의 최신 뉴스
The Escalator: Seres Therapeutics, Bavarian Nordic, Moderna and more - Medical Marketing and Media
Seres Therapeutics (MCRB) Projected to Post Earnings on Thursday - MarketBeat
Human Microbiome Therapeutics Market to Reach US$ 5.86 Billion - openPR.com
MCRB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Seres Therapeutics Announces Executive Leadership Changes and Promotions - The Globe and Mail
MCRB: Leadership transition and pipeline progress position the company for key clinical milestones in 2026 - TradingView
[8-K] Seres Therapeutics, Inc. Reports Material Event | MCRB SEC FilingForm 8-K - Stock Titan
Seres Therapeutics, Inc. Announces Executive and Management Changes - marketscreener.com
US Stocks Recap: Does Seres Therapeutics Inc have declining or rising EPSWeekly Trade Recap & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Panic Selling: How does Seres Therapeutics Inc perform in inflationary periodsJuly 2025 Reactions & Entry Point Confirmation Signals - baoquankhu1.vn
Seres Therapeutics (NASDAQ:MCRB) Shares Cross Below 50-Day Moving AverageWhat's Next? - MarketBeat
MCRB Technical Analysis & ETF Price Forecast - Intellectia AI
Layoff Tracker: Viatris Will Cut up to 10% of Global Workforce Over 3 Years - BioSpace
Setup Watch: Can Seres Therapeutics Inc outperform under higher oil prices2025 Big Picture & Consistent Growth Stock Picks - baoquankhu1.vn
Seres down after pausing investments for lead program - MSN
Seres Therapeutics (MCRB) officer trades RSU shares under 10b5-1 plan - Stock Titan
Market Review: Will Seres Therapeutics Inc benefit from green energy policiesQuarterly Portfolio Report & Technical Pattern Recognition Alerts - baoquankhu1.vn
$3.25+ Bn Human Microbiome Market Trends and Global Forecasts, 2035, Driven by Advancements in Microbiome Sequencing, Rising Investments in R&D, and Increasing Demand for Personalized Medicine - GlobeNewswire Inc.
Will Seres Therapeutics Inc. benefit from green energy policiesJuly 2025 Catalysts & Real-Time Buy Zone Alerts - mfd.ru
Is Seres Therapeutics Inc. stock a good choice for value investorsMarket Trend Review & Real-Time Volume Trigger Notifications - mfd.ru
Seres Therapeutics (NASDAQ:MCRB) Rating Lowered to Sell at Wall Street Zen - MarketBeat
MCRB Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Seres Therapeutics Status update Earnings Call Transcript - MarketBeat
Seres Pauses SER-155 Phase 2 Study, Cuts Costs - marketscreener.com
Seres Therapeutics Pauses SER-155 Investment, Cuts Workforce by 30% - Intellectia AI
Seres Therapeutics Stock Declines Amid Strategic Shift - Intellectia AI
Seres provides program and corporate updates and prioritizes emerging programs in inflammatory & immune diseases - marketscreener.com
MCRB Stock Declines As Seres Therapeutics Pauses SER-155 Phase 2 Study And Shrinks Headcount By 30% - Stocktwits
Seres Therapeutics pauses work on lead drug program amid cash crunch - The Business Journals
Seres Therapeutics Pauses Key Drug Study, Cuts Jobs To Save Cash - Bitget
Seres Shares Down After Co Pauses Drug Development, Lays Off Workers - marketscreener.com
Seres stock falls after pausing Phase 2 study and cutting workforce by 30% By Investing.com - Investing.com Nigeria
Seres stock falls after pausing Phase 2 study and cutting workforce by 30% - Investing.com UK
Biopharmaceutical company Seres Therapeutics, Inc. recently announced the implementation of a series of strategic adjustments aimed at extending its corporate operating cycle. - Bitget
Seres Provides Program and Corporate Updates and - GlobeNewswire
Seres Therapeutics (NASDAQ:MCRB) Stock Price Passes Below 50-Day Moving Average – Time to Sell? - Defense World
Seres Therapeutics (NASDAQ:MCRB) Stock Price Passes Below 50-Day Moving AverageTime to Sell? - MarketBeat
Can Seres Therapeutics Inc. stock beat market expectations this quarterLong Setup & Precise Swing Trade Alerts - mfd.ru
Seres Therapeutics announces leadership transition - MSN
Trading Recap: Should I invest in Seres Therapeutics Inc before earningsJuly 2025 Analyst Calls & Capital Efficiency Focused Ideas - baoquankhu1.vn
Seres Therapeutics: Strong SER-155 Data, But Dilution Risk Now Warrants A 'Hold' - Seeking Alpha
Microbiome Therapeutics for Patients and PhysiciansMedical / Health Care - Environmental XPRT
Dividend Watch: How does Seres Therapeutics Inc perform in inflationary periods2025 Performance Recap & Growth Oriented Trade Recommendations - baoquankhu1.vn
Investment Review: How does Seres Therapeutics Inc perform in inflationary periods2025 EndofYear Setup & Short-Term High Return Strategies - baoquankhu1.vn
Seres Therapeutics (NASDAQ:MCRB) Shares Cross Below 50-Day Moving Average – Should You Sell? - Defense World
Institution Moves: How does ALEX perform in inflationary periodsJuly 2025 Selloffs & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Aug Analyst Calls: Can Seres Therapeutics Inc weather a recessionMarket Growth Review & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Seres Therapeutics (NASDAQ:MCRB) Shares Pass Below 50 Day Moving Average – Time to Sell? - Defense World
Seres Therapeutics (NASDAQ:MCRB) Shares Pass Below 50 Day Moving AverageTime to Sell? - MarketBeat
Seres Therapeutics Inc (MCRB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.69%
0.68%
자본화:
|
볼륨(24시간):